RadOnc Smart Review

This is Episode 24b: The Nasopharynx Planning Workshop, which focuses on skull base abutment cases. In the preceding episodes, we established the clinical framework for nasopharyngeal carcinoma, encompassing anatomy, staging, EBV biology, systemic therapy sequencing, response assessment, and salvage strategies. We now transition to the planning workstation, where the decisions made within the next 45 minutes can determine whether a patient experiences acceptable function or suffers catastrophic late toxicity.

This is Episode 24: Nasopharynx IV Response Assessment and Salvage. Building upon the previous two episodes, we have established that nasopharyngeal carcinoma is a radiation-driven disease. We have reviewed the anatomy, EBV biology, staging, and evidence supporting concurrent chemoradiation, with or without induction. Now, we address the critical question patients will invariably pose: "Did it work?" More importantly, we will explore the appropriate course of action when the answer is negative. This episode delves into high-stakes scenarios. Recurrent NPC following definitive chemoradiation presents one of the most complex decision points in head and neck oncology. The available options include surgery, re-irradiation, or systemic therapy; however, an incorrect decision can have catastrophic consequences. Treatment-related mortality in the re-irradiation setting can exceed 10%. Risks such as carotid blowout syndrome, temporal lobe necrosis, and nasopharyngeal hemorrhage are not merely theoretical concerns but represent the daily realities of managing recurrent disease. By the conclusion of this episode, you will be equipped to assess response, determine appropriate intervention strategies, and counsel patients through what may be the most critical treatment decision of their lives.

This episode, number 23, focuses on Nasopharynx III Induction and Concurrent Systemic Therapy. Building on Episode 22, where we established NPC as a radiation-driven disease with unique anatomy and EBV biology, and Episode 22b, where we covered target volumes, we now delve into the systemic therapy backbone, the chemotherapy decisions that determine patient outcomes. This high-yield episode highlights the unique aspects of NPC systemic therapy compared to other head and neck cancers. Specifically, it explores why induction studies that failed in the oropharynx and larynx actually work in NPC, offering crucial insights for board exams.

In Episode 22, we framed nasopharyngeal carcinoma as a radiation-driven disease with distinct anatomy, EBV association, and AJCC 8 edition staging built around skull base landmarks. Now we do the part that oral boards loves: designing the plan.

This is Episode 22: Nasopharynx I Anatomy, E. B. V. Biology, and the Definitive R. T. Paradigm. Nasopharyngeal carcinoma is a board-favorite because it behaves unlike the rest of the head and neck. It is a radiation-first disease with skull base anatomy, retropharyngeal nodes as default, and a biomarker you are expected to talk about fluently: plasma E. B. V. D. N. A.

This is Episode 21: Oropharynx Capstone Mock Oral Boards. Today, we simulate the oral boards exam in five clinical blocks. Each block features a longitudinal case that escalates through workup, staging, treatment selection, planning priorities, and outcomes. Then we close each block with a shorter twist that tests a key decision pivot. Treat this like a live exam. After every question, you will hear: "Pause for listener to formulate response." Use that pause. Then compare your answer to the model response.

This is Episode 20: Functional Outcomes and Survivorship in Oropharyngeal Cancer. Today is about what boards actually test when they say “survivorship”: whether you understand the *functional price* of cure, and whether you can prove you planned thoughtfully to reduce that price. This episode is going to be constraint-forward. We are going to use a conventional fractionation constraint library (QUANTEC and major protocol-style constraints, plus some institutional planning goals) as the backbone, and we’ll keep circling back to the handful of numbers you must be able to say out loud under pressure.

Today is the curveball episode. Boards love these scenarios because they test judgment, sequencing, and restraint. We will do three things. First, we will contrast the tobacco-associated, p16-negative oropharynx patient with the favorable HPV-positive population, because there is no de-escalation lane here. Second, we will develop a clean, board-safe, and unknown primary workup that escalates logically and efficiently — ultimately leading to the modern transoral diagnostic step, which can localize the primary at high rates. Third, we will walk through salvage strategy selection in previously irradiated patients — who to push, who to spare, and how to talk about it.

Welcome back to Rad Onc Smart Review, Head and Neck edition. This is Episode 18B: The Post-Operative Oropharynx Planning Workshop. Episode Eighteen was the clinic decision: who gets observation, who gets P-O-R-T, and who needs post-op chemoradiation after transoral surgery for H-P-V-positive oropharyngeal cancer. Episode Eighteen-B is the execution: you already decided “radiation alone” or “chemoradiation.” Now you have to contour the surgical bed, choose the right neck volumes, pick a defensible dose tier, and protect swallowing in a patient who has an excellent prognosis. Today is about post-op oropharynx specifically: tonsil, base of tongue, and the risk-adapted post-Tors framework built around ECOG ACRIN E-3-3-1-1.

This is Episode 18: TORS and De-Escalation. Today we tackle one of the most controversial and actively evolving areas in head and neck oncology: the role of transoral robotic surgery and treatment de-intensification for H-P-V-positive oropharyngeal cancer. This is exceptionally high-yield for boards because examiners love to test whether you can distinguish proven standards from promising-but-investigational strategies. Here is the core tension you must understand: H-P-V-positive oropharyngeal cancer hasan excellent prognosis with standard chemoradiation, with five-year overall survival exceeding eighty-five percent. This favorable biology has generated enormous enthusiasm for de-escalation, meaning reducing treatment intensity to preserve function while maintaining cure. But enthusiasm is not evidence. Multiple de-escalation strategies have failed in Phase Three testing, and the examiner will probe whether you know the difference between what is proven and what remains investigational. By the end of this episode, you will be able to articulate TORS candidacy criteria, navigate the E-C-O-G-A-C-R-I-N E-three-three-eleven risk stratification system, explain why N-R-G H-N-zero-zero-five closed its dose-reduced arm, and deliver board-safe answers that acknowledge nuance without overstating evidence.